FDA grants fast track status to Agenus’ colorectal cancer combination therapy
2023-04-19
临床1期快速通道临床2期临床结果
Preview
来源: Pharmaceutical Technology
Tumour invasion into a vein in a case of colorectal cancer. Credit: Patho / commons.wikimedia.org.
The US Food and Drug Administration (FDA) has granted Fast Track designation for Agenus’ combination therapy for the treatment of colorectal cancer.
The FDA awarded the Fast Track status for the investigation of a botensilimab (AGEN1181) and balstilimab (AGEN2034) combination.
The combination therapy has been approved to treat non-microsatellite instability-high (non-MSI-H)/deficient mismatch repair metastatic colorectal cancer patients, with no signs of active liver involvement.
The designation covers patients who are heavily pre-treated and show resistance or intolerance to fluoropyrimidine, irinotecan and oxaliplatin.
It also includes people who have previously received a vascular endothelial growth factor inhibitorvascular endothelial growth factor inhibitor, an epidermal growth factor receptor inhibitorepidermal growth factor receptor inhibitor and/or a BRAF (v-raf murine sarcoma viral oncogene homolog B1) inhibitor(v-raf murine sarcoma viral oncogene homolog B1) inhibitor, if indicated.
Agenus chief medical officer Dr Steven O’Day stated: “We are pleased that the FDA has granted Fast Track designation for the combination of botensilimab with balstilimab in patients with non-MSI-H colorectal cancer, recognising the high unmet medical need in this population.
“The Fast Track designation offers important benefits, including the potential eligibility for a Priority Review, and we will be working with the FDA and all key stakeholders to rapidly advance the botensilimab/balstilimab combination in colorectal cancer as well as other solid tumour indications.”
The company is currently conducting a randomised, global Phase II trial of the combination of botensilimab and Agenus’ PD-1 antibody balstilimab versus standard of care in patients with non-MSI-H colorectal cancer.
A new multifunctional CTLA-4 investigational antibody, botensilimab has been designed for expanding the clinical benefits to cold tumours which did not respond to standard of care or investigational treatments.
In a Phase Ib clinical trial involving more than 350 participants, it showed clinical responses in nine solid tumour cancers either alone or along with balstilimab.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。